ArticleDermatology research and practice2026
Increased IL-23 is Associated to Heliotrope Sign in Multivariate Model on Idiopathic Inflammatory Myopathies.
Article in Dermatology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heliotrope rash is a pathognomonic feature of dermatomyositis (DM); however, the molecular pathways implicated in cutaneous involvement have not been fully explored. Although the IL-23/Th17 axis has been implicated in inflammatory and autoimmune diseases, the clinical significance of circulating IL-23 across the idiopathic inflammatory myopathy (IIM) spectrum, particularly in cutaneous disease expression, remains insufficiently defined. In this cross-sectional study, we aimed to quantify serum IL-23 levels in patients with IIM and evaluate their association with cutaneous involvement, including overall skin disease activity assessed by the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the presence of specific skin manifestations, particularly pathognomonic lesions, using a univariate analysis. Serum IL-23 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) in patients with IIM and healthy controls (HCs), and their relationships with clinical and cutaneous variables were analyzed using univariable and multivariable approaches. Higher IL-23 levels were associated with cutaneous involvement, especially with pathognomonic skin manifestations and, most notably, heliotrope sign. IL-23 also showed a positive correlation with CDASI activity; the relationship with heliotrope sign remained consistent. Applying a multivariate model, heliotrope rash remained the only independent factor associated with IL-23 levels: in other words, IL-23 increases by 437.3 pg/mL when heliotrope is present. These findings suggest that IL-23 may be preferentially associated with a cutaneous phenotype characterized by heliotrope rash, rather than with global skin burden alone.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.